文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.

作者信息

Bennett Diane E, Bertagnolio Silvia, Sutherland Donald, Gilks Charles F

机构信息

World Health Organization, Geneva, Switzerland.

出版信息

Antivir Ther. 2008;13 Suppl 2:1-13.


DOI:
PMID:18578063
Abstract

Antiretroviral treatment (ART) for HIV is being scaled up rapidly in resource-limited countries. Treatment options are simplified and standardized, generally with one potent first-line regimen and one potent alternate first-line regimen recommended. Widespread HIV drug resistance (HIVDR) was initially feared, but reports from resource-limited countries suggest that initial ART programmes are as effective as in resource-rich countries, which should limit HIV drug resistance if programme effectiveness continues during scale-up. ART interruptions must be minimized to maintain viral suppression on the first-line regimen for as long as possible. Lack of availability of appropriate second-line drugs is a concern, as is the additional accumulation of resistance mutations in the absence of viral load testing to determine failure. The World Health Organization (WHO) recommends a minimum-resource strategy for prevention and assessment of HIVDR in resource-limited countries. The WHO's Global Network HIVResNet provides standardized tools, training, technical assistance, laboratory quality assurance, analysis of results and recommendations for guidelines and public health action. National strategies focus on assessments to guide immediate public health action to improve ART programme effectiveness in minimizing HIVDR and to guide regimen selection. Globally, WHO HIVResNet collects and analyses data to support evidence-based international policies and guidelines. Financial support is provided by major international organizations and technical support from HIVDR experts worldwide. As of December 2007, 25 countries were planning or implementing the strategy; seven countries report results in this supplement.

摘要

相似文献

[1]
The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.

Antivir Ther. 2008

[2]
World Health Organization/HIVResNet Drug Resistance Laboratory Strategy.

Antivir Ther. 2008

[3]
World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.

Antivir Ther. 2008

[4]
Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006.

Antivir Ther. 2008

[5]
Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi.

Antivir Ther. 2008

[6]
HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam.

Antivir Ther. 2008

[7]
Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania.

Antivir Ther. 2008

[8]
HIV drug resistance transmission threshold survey in Bangkok, Thailand.

Antivir Ther. 2008

[9]
Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia.

Antivir Ther. 2008

[10]
Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment.

Antivir Ther. 2008

引用本文的文献

[1]
The urgent need for newer drugs in routine HIV treatment in Africa: the case of Ghana.

Front Epidemiol. 2025-3-14

[2]
Strengthening and enhancing national antiretroviral drug resistance surveillance in Zimbabwe-A country that has reached UNAIDS 95-95-95 amongst adults.

Front Public Health. 2024-2-14

[3]
Enriching Data Science and Health Care Education: Application and Impact of Synthetic Data Sets Through the Health Gym Project.

JMIR Med Educ. 2024-1-16

[4]
Towards a post-pandemic future for global pathogen genome sequencing.

PLoS Biol. 2023-8

[5]
Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection.

J Virus Erad. 2023-3-4

[6]
HIV-1 Drug Resistance Profiles of Low-Level Viremia Patients and Factors Associated With the Treatment Effect of ART-Treated Patients: A Cross-Sectional Study in Jiangsu, China.

Front Public Health. 2022

[7]
Consistent condom utilization and associated factors among HIV positive clients attending ART clinic at Pawi general hospital, North West Ethiopia.

PLoS One. 2021

[8]
Transmitted Drug Resistance in Antiretroviral Therapy-Naive Persons With Acute/Early/Primary HIV Infection: A Systematic Review and Meta-Analysis.

Front Pharmacol. 2021-11-24

[9]
Point-of-care viral load testing among adolescents and youth living with HIV in Haiti: a protocol for a randomised trial to evaluate implementation and effect.

BMJ Open. 2020-8-31

[10]
HIV-1 molecular epidemiology and drug resistance-associated mutations among treatment-naïve blood donors in China.

Sci Rep. 2020-5-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索